Search Within

Tiffany A Traina

Formats
  1. Meeting Abstract (137)
  2. Journal Article (95)
  3. Book Section (8)
  4. Review (6)
  5. Book Whole (2)
  6. Guidelines (1)
  7. Miscellaneous (1)
Groups
  1. Breast Medicine Service (250)
  2. Department of Medicine (250)
  3. Solid Tumor Oncology Division (250)
  4. Survivorship Research (250)
  5. Epidemiology and Biostatistics (99)
  6. Biostatistics Service (85)

More Groups

People
  1. Clifford Hudis (95)
  2. Sujata Patil (62)
  3. Ayca Gucalp (59)
  4. Larry Norton (56)
  5. Maura Dickler (34)
  6. Diana Lake (33)

More People

Years
  1. 2025 (3)
  2. 2024 (16)
  3. 2023 (8)
  4. 2022 (13)
  5. 2021 (17)
  6. 2020 (16)

More Years

Publications
  1. Journal of Clinical Oncology (76)
  2. Cancer Research (44)
  3. Breast Cancer Research and Treatment (16)
  4. Annals of Oncology (14)
  5. Clinical Cancer Research (11)
  6. Clinical Breast Cancer (7)

More Publications

Publishers
  1. American Society of Clinical Oncology (77)
  2. American Association for Cancer Research (55)
  3. Springer (33)
  4. Elsevier Inc. (23)
  5. Oxford University Press (16)
  6. Future Medicine (5)

More Publishers

Results (250)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1/2 study of once-daily oral VT-464 in patients with advanced androgen receptor (AR) positive triple negative (TNBC) or estrogen receptor (ER) positive breast cancer (BC)
    Meeting Abstract

    Gucalp, A.; Hudis, C.; Norton, L.; Patil, S.; Kurman, M. R.; Eisner, J. R.; Moore, W. R.; Traina, T. A.
    Cancer Research (2016)

    Fulltext@MSK | Save
  • Improved clinical outcomes on enzalutamide observed in patients with PREDICT AR+ triple-negative breast cancer: Prognosis or prediction?
    Meeting Abstract

    Miller, K.; Krop, I.; Schwartzberg, L.; Abramson, V.; Garcia-Estevez, L.; Eakle, J.; Nanda, R.; Yardley, D.; Ademuyiwa, F.; Chan, S.; more...
    Cancer Research (2016)

    Fulltext@MSK | Save
  • Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer: A systematic review and meta-analysis
    Journal Article

    Munhoz, R. R.; Pereira, A. A.; Sasse, A. D.; Hoff, P. M.; Traina, T. A.; Hudis, C. A.; Marques, R. J.
    JAMA Oncology (2016)

    Fulltext@MSK | Save
  • A pilot study of dose-dense paclitaxel with trastuzumab and lapatinib for node-negative HER2-overexpressed breast cancer
    Journal Article

    Iyengar, N. M.; Fornier, M. N.; Sugarman, S. M.; Theodoulou, M.; Troso-Sandoval, T. A.; D'Andrea, G. M.; Drullinsky, P. R.; Gajria, D.; Goldfarb, S. B.; Comen, E. A.; more...
    Clinical Breast Cancer (2016)

    Fulltext@MSK | Save
  • Phase I study of PI3Kα inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Hamilton, N.; Caravella, B. A.; Zamora, S.; Dang, C.; Gilewski, T.; Traina, T.; Comen, E.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Triple negative breast cancer: The role of androgen receptor and its inhibitors
    Meeting Abstract

    Hudis, C. A.; Traina, T.
    Breast (2015)

    Fulltext@MSK | Save
  • Overall survival (OS) from the phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) signaling inhibitor, in AR+ advanced triple-negative breast cancer (aTNBC)
    Meeting Abstract

    Cortes, J.; Crown, J.; Awada, A.; Schmid, P.; Gianni, L.; Garcia-Estevez, L.; Martinez-Janez, N.; Chan, S.; Steinberg, J. L.; Blaney, M.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • Significance of circulating tumor cells in metastatic triple-negative breast cancer patients within a randomized, phase II trial: TBCRC 019
    Journal Article

    Paoletti, C.; Li, Y.; Muñiz, M. C.; Kidwell, K. M.; Aung, K.; Thomas, D. G.; Brown, M. E.; Abramson, V. G.; Irvin, W. J. Jr; Lin, N. U.; more...
    Clinical Cancer Research (2015)

    Fulltext@MSK | Save
  • TBCRC 019: A phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 monoclonal antibody tigatuzumab in patients with triple-negative breast cancer
    Journal Article

    Forero-Torres, A.; Varley, K. E.; Abramson, V. G.; Li, Y.; Vaklavas, C.; Lin, N. U.; Liu, M. C.; Rugo, H. S.; Nanda, R.; Storniolo, A. M.; more...
    Clinical Cancer Research (2015)

    Fulltext@MSK | Save
  • Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR plus triplenegative breast cancer (TNBC)
    Meeting Abstract

    Traina, T. A.; Miller, K.; Yardley, D. A.; O'Shaughnessy, J.; Cortes, J.; Awada, A.; Kelly, C. M.; Trudeau, M. E.; Schmid, P.; Gianni, L.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save